This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
converting enzyme | 1037 |
ang ii | 672 |
angiotensin ii | 558 |
ace inhibitors | 476 |
blood pressure | 319 |
heart failure | 306 |
angiotensin system | 262 |
acute respiratory | 245 |
angiotensin converting | 227 |
respiratory syndrome | 208 |
ace activity | 206 |
angiotensin i | 202 |
severe acute | 182 |
myocardial infarction | 176 |
ace inhibitor | 174 |
receptor blockers | 162 |
coronavirus disease | 159 |
novel coronavirus | 154 |
ang i | 148 |
lung injury | 140 |
angiotensin receptor | 139 |
ii receptor | 134 |
syndrome coronavirus | 131 |
ace inhibition | 128 |
enzyme inhibitors | 127 |
spike protein | 120 |
smooth muscle | 105 |
ii type | 104 |
cardiovascular disease | 104 |
hereditary angioedema | 104 |
active site | 103 |
sars coronavirus | 98 |
amino acid | 96 |
inh concentrate | 93 |
angiotensinconverting enzyme | 89 |
left ventricular | 88 |
human ace | 87 |
inh deficiency | 86 |
gene expression | 85 |
endothelial cells | 85 |
type receptor | 85 |
nitric oxide | 80 |
severe covid | 80 |
increased risk | 79 |
clinical trials | 75 |
ace expression | 72 |
risk factors | 72 |
amino acids | 72 |
viral entry | 71 |
ace gene | 71 |
nervous system | 71 |
respiratory distress | 71 |
enzyme inhibition | 71 |
epithelial cells | 70 |
factor xii | 70 |
neutral endopeptidase | 70 |
aldosterone system | 69 |
may also | 64 |
ii levels | 62 |
cord uid | 62 |
distress syndrome | 62 |
doc id | 62 |
side effects | 61 |
mas receptor | 61 |
receptor antagonist | 61 |
db mice | 59 |
kidney disease | 58 |
type i | 58 |
type ii | 56 |
clinical characteristics | 55 |
oxidative stress | 55 |
united states | 55 |
i arbs | 55 |
animal models | 53 |
acute lung | 52 |
diabetes mellitus | 52 |
human angiotensin | 52 |
coronary artery | 51 |
renin angiotensin | 49 |
host cells | 49 |
blood flow | 49 |
ace protein | 48 |
significantly increased | 48 |
hypertensive rats | 48 |
endothelial dysfunction | 48 |
clinical trial | 48 |
protein expression | 47 |
inhibitor therapy | 47 |
middle east | 46 |
severe disease | 46 |
systematic review | 46 |
coronavirus infection | 46 |
vascular smooth | 45 |
human coronavirus | 44 |
increased ace | 44 |
type diabetes | 43 |
critically ill | 43 |
heart rate | 43 |
receptor blocker | 42 |
east respiratory | 42 |
diabetic nephropathy | 42 |
cell surface | 42 |
mas axis | 41 |
intensive care | 40 |
inhibitor deficiency | 40 |
knockout mice | 40 |
hypertensive patients | 40 |
growth factor | 40 |
ace ace | 40 |
pulmonary hypertension | 40 |
adverse effects | 40 |
angioedema attacks | 40 |
channel blockers | 39 |
respiratory tract | 39 |
recombinant human | 38 |
hereditary angioneurotic | 38 |
muscle cells | 38 |
cohort study | 38 |
infected patients | 38 |
immune system | 38 |
potentiating peptides | 38 |
renin receptor | 38 |
risk factor | 38 |
cell entry | 38 |
calcium channel | 38 |
receptor blockade | 38 |
active sites | 38 |
herd immunity | 38 |
heart disease | 37 |
spontaneously hypertensive | 37 |
somatic ace | 37 |
beta blockers | 37 |
enzyme inhibitor | 37 |
diabetic mice | 37 |
viral replication | 37 |
system inhibitors | 36 |
nh gene | 36 |
clinical course | 36 |
induced lung | 36 |
among patients | 36 |
transgenic mice | 36 |
cytokine storm | 36 |
receptor antagonists | 36 |
world health | 35 |
sars cov | 35 |
kcal mol | 35 |
functional receptor | 35 |
patients infected | 35 |
health organization | 35 |
insulin administration | 35 |
central nervous | 35 |
host cell | 34 |
enzyme gene | 34 |
also known | 34 |
congestive heart | 34 |
disease severity | 34 |
ventricular dysfunction | 34 |
ang iv | 34 |
cont mice | 34 |
vascular endothelial | 33 |
important role | 33 |
ischemic stroke | 33 |
cardiac output | 33 |
related carboxypeptidase | 32 |
inflammatory cytokines | 32 |
higher risk | 32 |
lung fibrosis | 32 |
ejection fraction | 31 |
ill patients | 31 |
deletion polymorphism | 31 |
hae attacks | 31 |
brain ras | 31 |
enzyme activity | 31 |
deficient mice | 31 |
binding site | 31 |
cardiovascular diseases | 31 |
copyright holder | 30 |
esterase inhibitor | 30 |
patients receiving | 30 |
output loss | 30 |
immune response | 30 |
crystal structure | 30 |
i converting | 30 |
angioneurotic edema | 29 |
protease inhibitor | 29 |
potential therapeutic | 29 |
hae type | 29 |
ace levels | 28 |
serine protease | 28 |
inhibitor gene | 28 |
mortality rate | 28 |
european society | 28 |
molecular weight | 28 |
hospitalized patients | 28 |
artery disease | 28 |
granted medrxiv | 28 |
death rates | 28 |
viral infections | 28 |
beneficial effects | 28 |
author funder | 28 |
ace may | 27 |
receptor stimulation | 27 |
converts angiotensin | 27 |
ang iii | 27 |
substrate specificity | 27 |
vascular resistance | 27 |
coronavirus spike | 27 |
soluble ace | 27 |
organ damage | 27 |
binding domain | 27 |
vascular permeability | 27 |
ace ang | 27 |
essential hypertension | 26 |
mrna expression | 26 |
patients treated | 26 |
chronic kidney | 26 |
drosophila melanogaster | 26 |
cov infection | 26 |
enzymatic activity | 26 |
icu admission | 26 |
insect ace | 26 |
type iii | 26 |
antihypertensive drugs | 26 |
lung tissue | 26 |
plasminogen activator | 26 |
viral load | 25 |
mineralocorticoid receptor | 25 |
ace homologues | 25 |
immune responses | 25 |
nonallergic angioedema | 25 |
angiotensin peptides | 25 |
bradykinin potentiating | 25 |
risk group | 25 |
atrial fibrillation | 25 |
may contribute | 25 |
rbd ace | 25 |
pressure regulation | 24 |
receptor ace | 24 |
transforming growth | 24 |
enzyme angiotensin | 24 |
action potential | 24 |
receptor binding | 24 |
gpiase activity | 24 |
gastrointestinal tract | 24 |
receptor gene | 24 |
fatality rate | 24 |
term prophylaxis | 24 |
anchored proteins | 24 |
plasma kallikrein | 24 |
spike proteins | 24 |
chronic heart | 24 |
clinical features | 24 |
significantly higher | 24 |
mouse model | 24 |
blood vessels | 24 |
control group | 24 |
system blockers | 24 |
may result | 24 |
human lung | 24 |
protein kinase | 24 |
patients taking | 23 |
two active | 23 |
death rate | 23 |
viral rna | 23 |
angiotensin type | 23 |
peer review | 23 |
brain tissue | 23 |
reninangiotensin system | 23 |
cell membrane | 23 |
renal disease | 23 |
acc aha | 23 |
sequence identity | 23 |
uncaria tomentosa | 23 |
inflammatory response | 23 |
care unit | 23 |
right ventricle | 23 |
abdominal pain | 23 |
attenuated androgens | 23 |
peptidase activity | 23 |
phase ii | 23 |
ras components | 22 |
insertion deletion | 22 |
heart function | 22 |
influenza virus | 22 |
inh function | 22 |
laryngeal edema | 22 |
lopinavir ritonavir | 22 |
cleavage site | 22 |
lung failure | 22 |
gene promoter | 22 |
public health | 22 |
ace receptor | 22 |
retrospective cohort | 22 |
clinical studies | 22 |
case series | 21 |
viral infection | 21 |
controlled trial | 21 |
late stages | 21 |
contact system | 21 |
novel angiotensin | 21 |
expression levels | 21 |
plasma levels | 21 |
right ventricular | 21 |
hereditary angio | 21 |
receptor activation | 21 |
zinc ion | 21 |
crucial role | 21 |
renin inhibitor | 21 |
kinin system | 21 |
ace knockout | 21 |
wide range | 21 |
widely used | 21 |
mechanical ventilation | 21 |
animal studies | 21 |
tissue distribution | 21 |
acute myocardial | 21 |
recombinant ace | 21 |
may increase | 21 |
hepatic fibrosis | 21 |
version posted | 21 |
receptor expression | 20 |
natriuretic peptides | 20 |
lung cells | 20 |
statistically significant | 20 |
virus infection | 20 |
blood glucose | 20 |
ii receptors | 20 |
clinical manifestations | 20 |
proximal tubule | 20 |
coupled receptor | 20 |
cardiac angiotensin | 20 |
posted june | 20 |
protective role | 20 |
replacement therapy | 20 |
inhibitors arbs | 20 |
functional expression | 20 |
ace axis | 20 |
new coronavirus | 20 |
convalescent plasma | 20 |
circulating ace | 20 |
inherited angioedema | 20 |
affected patients | 20 |
tg mice | 20 |
renin activity | 20 |
receptor axis | 20 |
refractory period | 19 |
portal pressure | 19 |
current smokers | 19 |
liver fibrosis | 19 |
catalytically active | 19 |
spike glycoprotein | 19 |
hospital mortality | 19 |
akita mice | 19 |
lower respiratory | 19 |
clinical data | 19 |
left ventricle | 19 |
cardiovascular system | 19 |
ventricular hypertrophy | 19 |
respiratory failure | 19 |
enzyme protects | 19 |
mortality rates | 19 |
liver disease | 19 |
structural proteins | 19 |
therapeutic target | 19 |
increased expression | 19 |
general population | 19 |
reactive oxygen | 19 |
case fatality | 19 |
increased levels | 19 |
human plasma | 18 |
myocardial injury | 18 |
signal transduction | 18 |
ii formation | 18 |
kidney injury | 18 |
receptor agonist | 18 |
plasma concentrations | 18 |
corona virus | 18 |
protective effects | 18 |
alveolar epithelial | 18 |
ace angiotensin | 18 |
natriuretic peptide | 18 |
sympathetic nervous | 18 |
two homologous | 18 |
pulmonary fibrosis | 18 |
molecular mechanisms | 18 |
monoclonal antibody | 18 |
tranexamic acid | 18 |
medrxiv preprint | 18 |
plasma membrane | 18 |
sars virus | 18 |
target cells | 17 |
first step | 17 |
converting enzymes | 17 |
angiotensinogen gene | 17 |
inhibitor binding | 17 |
american college | 17 |
acute attacks | 17 |
pulmonary disease | 17 |
anchored protein | 17 |
odds ratio | 17 |
inh concentration | 17 |
recent studies | 17 |
adam tace | 17 |
another study | 17 |
severe lethal | 17 |
highly expressed | 17 |
receptor mas | 17 |
glucose levels | 17 |
lung fibroblasts | 17 |
patients admitted | 17 |
oxide synthase | 17 |
early stage | 17 |
high risk | 17 |
human renin | 17 |
protease tmprss | 17 |
randomized clinical | 17 |
necrosis factor | 17 |
renal function | 17 |
binding sites | 16 |
two domains | 16 |
activity ratio | 16 |
essential regulator | 16 |
two groups | 16 |
upper respiratory | 16 |
virus entry | 16 |
arterial hypertension | 16 |
immune cells | 16 |
binding pocket | 16 |
health care | 16 |
acquired angioedema | 16 |
european countries | 16 |
ace homologue | 16 |
mitral valve | 16 |
coronavirus sars | 16 |
previous studies | 16 |
terminal domain | 16 |
drosophila ace | 16 |
renal ace | 16 |
reduced ace | 16 |
plasma renin | 16 |
bradykinin receptor | 16 |
renin inhibitors | 16 |
cardiac function | 16 |
complement activation | 16 |
homologous domains | 16 |
high blood | 16 |
arbs treatment | 16 |
confirmed cases | 16 |
proximal tubular | 16 |
diabetic kidney | 16 |
pulmonary vascular | 16 |
home therapy | 16 |
gene transcription | 16 |
stem cells | 16 |
protective effect | 16 |
oxygen species | 16 |
authors declare | 16 |
clinical symptoms | 16 |
inhibitors angiotensin | 16 |
acute abdominal | 16 |
circulating ras | 16 |
gene polymorphisms | 16 |
china clinical | 15 |
cardiovascular risk | 15 |
reuse allowed | 15 |
new york | 15 |
ebola virus | 15 |
tissue ras | 15 |
ace mrna | 15 |
aldosterone synthase | 15 |
binding affinity | 15 |
signaling pathways | 15 |
hungarian hae | 15 |
observational study | 15 |
drug design | 15 |
related angioedema | 15 |
neutralizing antibodies | 15 |
allowed without | 15 |
ace deletion | 15 |
chronic obstructive | 15 |
tissue ace | 15 |
rights reserved | 15 |
studies using | 15 |
specific substrate | 15 |
african americans | 15 |
dengue virus | 15 |
inhibitory activity | 15 |
innate immune | 15 |
rat model | 15 |
cell proliferation | 15 |
heart association | 15 |
without permission | 15 |
functional activity | 15 |
interventricular septum | 15 |
respiratory disease | 15 |
higher levels | 15 |
serine proteases | 15 |
antihypertensive agents | 15 |
akita hnrnpf | 15 |
may lead | 15 |
patients without | 15 |
catalytic activity | 15 |
biologically active | 15 |
gene polymorphism | 15 |
binding protein | 15 |
rats angiotensin | 15 |
entry depends | 15 |
lung damage | 15 |
portal hypertension | 15 |
catalytic domain | 15 |
clinically proven | 15 |
pediatric patients | 15 |
present study | 15 |
diabetic patients | 15 |
adrenal gland | 15 |
inhibitor treatment | 15 |
angiotensin iv | 15 |
mammalian ace | 15 |
key role | 15 |
disease control | 15 |
db db | 15 |
proximal tubules | 15 |
proven protease | 15 |
higher mortality | 15 |
data suggest | 15 |
membrane protein | 15 |
human airway | 15 |
control study | 14 |
chronic use | 14 |
task force | 14 |
gpi anchor | 14 |
mice lacking | 14 |
i hereditary | 14 |
angioneurotic oedema | 14 |
cardiac fibrosis | 14 |
molecular biology | 14 |
receptor subtypes | 14 |
many different | 14 |
different tissues | 14 |
angiotensin systems | 14 |
kinin peptides | 14 |
aceis arbs | 14 |
human homolog | 14 |
factor xiia | 14 |
obstructive pulmonary | 14 |
major role | 14 |
phase i | 14 |
angiotensin receptors | 14 |
right coronary | 14 |
new therapeutic | 14 |
ii generation | 14 |
induced acute | 14 |
syncytial virus | 14 |
clinical implications | 14 |
clinical use | 14 |
randomised trial | 14 |
creative commons | 14 |
protease inhibitors | 14 |
tissue kallikrein | 14 |
tumor necrosis | 14 |
american heart | 14 |
respiratory syncytial | 14 |
glycosylation sites | 14 |
hypertension hospitalized | 14 |
gender differences | 14 |
side chain | 14 |
angioedema associated | 14 |
increased ang | 14 |
edematous attacks | 14 |
cause mortality | 14 |
icu care | 14 |
might also | 14 |
antiviral activity | 14 |
cell types | 14 |
randomized controlled | 14 |
second messenger | 14 |
acute attack | 14 |
neprilysin inhibitor | 14 |
dipeptidyl peptidase | 14 |
aortic stenosis | 14 |
proteolytic activation | 14 |
severe cases | 14 |
significantly decreased | 14 |
clinical practice | 14 |
brush border | 14 |
intracellular calcium | 13 |
induced hypertension | 13 |
cell culture | 13 |
deaths due | 13 |
pulmonary vasoconstriction | 13 |
potential role | 13 |
receiving ace | 13 |
may occur | 13 |
classical ras | 13 |
insensitive carboxypeptidase | 13 |
observational studies | 13 |
increasing ace | 13 |
peptide levels | 13 |
acid sequence | 13 |
cardiovascular events | 13 |
rat heart | 13 |
western blotting | 13 |
human cells | 13 |
tubular cells | 13 |
ii production | 13 |
rat brain | 13 |
whereas ace | 13 |
understanding sars | 13 |
less likely | 13 |
hypertensive subjects | 13 |
liquid chromatography | 13 |
inh concentrations | 13 |
elderly patients | 13 |
endothelial function | 13 |
specific inhibitor | 13 |
significant increase | 13 |
adverse events | 13 |
specific ace | 13 |
local ras | 13 |
integral membrane | 13 |
ras system | 13 |
tissue injury | 13 |
clinical outcomes | 13 |
angioedema caused | 13 |
potent inhibitor | 13 |
biological peptides | 13 |
viral loads | 13 |
retrospective study | 13 |
stroke volume | 13 |
lethal disease | 13 |
antifibrinolytic agents | 13 |
aortic valve | 13 |
taking ace | 13 |
guinea pig | 13 |
late stage | 13 |
molecular cloning | 13 |
ethnic groups | 13 |
patients hospitalized | 13 |
sex hormones | 13 |
catalytic site | 13 |
high levels | 13 |
renal angiotensin | 13 |
md simulation | 13 |
clinical presentation | 13 |
adjusted hr | 13 |
mortality among | 13 |
peripheral vascular | 13 |
ventricular arrhythmias | 13 |
acid residues | 13 |
adult inpatients | 13 |
renin prorenin | 13 |
specific inhibitors | 13 |
uncaric acid | 13 |
local renin | 13 |
rna viruses | 13 |
ace i | 13 |
may cause | 13 |
ace deficiency | 12 |
may play | 12 |
activator inhibitor | 12 |
decreased ace | 12 |
therapeutic implications | 12 |
cell death | 12 |
chain reaction | 12 |
recurrent angioedema | 12 |
airway epithelium | 12 |
like activity | 12 |
insulin resistance | 12 |
selective inhibitors | 12 |
lung disease | 12 |
results suggest | 12 |
ventricular tachycardia | 12 |
cardiovascular effects | 12 |
nep may | 12 |
made available | 12 |
monoclonal antibodies | 12 |
increased mortality | 12 |
transmembrane domain | 12 |
drug classes | 12 |
side effect | 12 |
possible role | 12 |
significant difference | 12 |
myocardial ischemia | 12 |
like enzyme | 12 |
optimal lockdown | 12 |
small intestine | 12 |
high level | 12 |
human heart | 12 |
type mice | 12 |
injury angiotensin | 12 |
dependent enhancement | 12 |
coronary blood | 12 |
aldosterone secretion | 12 |
studies showed | 12 |
antiviral drugs | 12 |
may explain | 12 |
terminal catalytic | 12 |
raas antagonists | 12 |
also observed | 12 |
ectodomain shedding | 12 |
incubation period | 12 |
orally active | 12 |
beta blocker | 12 |
significantly reduced | 12 |
molecular basis | 12 |
mas receptors | 12 |
polymerase chain | 12 |
glomerular injury | 12 |
recent study | 12 |
significant differences | 12 |
mild symptoms | 12 |
nuclear factor | 12 |
attack therapy | 12 |
transmission rate | 12 |
one study | 12 |
dendritic cells | 12 |
ace also | 12 |
active renin | 12 |
acute coronary | 12 |
also showed | 12 |
coronary sinus | 12 |
sars pathogenesis | 12 |
factors associated | 12 |
membrane fusion | 12 |
bat origin | 12 |
patients may | 12 |
taken together | 12 |
chronic angiotensin | 12 |
coronary arteries | 12 |
danazol treatment | 12 |
dipeptidyl carboxypeptidase | 12 |
harmful effects | 12 |
physiological functions | 12 |
risk patients | 12 |
study group | 12 |
inflammatory effects | 12 |
endothelial cell | 12 |
transgenic rats | 12 |
well tolerated | 12 |
weight kininogen | 12 |
rna polymerase | 12 |
promoter activity | 12 |
several studies | 12 |
endopeptidase activity | 12 |
using ace | 12 |
administration significantly | 11 |
biological activity | 11 |
hydrogen bond | 11 |
younger subjects | 11 |
domain specific | 11 |
determine whether | 11 |
infected individuals | 11 |
inh protein | 11 |
also found | 11 |
failure angiotensin | 11 |
related coronavirus | 11 |
mg daily | 11 |
high mortality | 11 |
potent vasoconstrictor | 11 |
sequence homology | 11 |
tissue angiotensin | 11 |
disease course | 11 |
vascular disease | 11 |
selective inhibitor | 11 |
angina pectoris | 11 |
drosophila angiotensin | 11 |
virus may | 11 |
ii pneumocytes | 11 |
serum samples | 11 |
circulating ang | 11 |
prorenin receptor | 11 |
controlled trials | 11 |
chloride ion | 11 |
oral contraception | 11 |
coronavirus nl | 11 |
renin gene | 11 |
isolated perfused | 11 |
rbd binding | 11 |
two isoforms | 11 |
pulmonary blood | 11 |
normoxic recovery | 11 |
female patients | 11 |
position statement | 11 |
ischaemic heart | 11 |
vasoactive peptides | 11 |
classical pathway | 11 |
cardiovascular death | 11 |
pathological conditions | 11 |
inhibitory effect | 11 |
adipose tissue | 11 |
within hours | 11 |
right atrium | 11 |
physiological processes | 11 |
infectious diseases | 11 |
activated protein | 11 |
mas pathway | 11 |
two patients | 11 |
reduced ejection | 11 |
male fertility | 11 |
renal injury | 11 |
many patients | 11 |
hfsa acc | 11 |
outflow tract | 11 |
hemoregulatory peptide | 11 |
catalytic domains | 11 |
brain renin | 11 |
bothrops jararaca | 11 |
coronavirus infections | 11 |
arachidonic acid | 11 |
alveolar macrophages | 11 |
testis ace | 11 |
randomized trial | 11 |
airway epithelia | 11 |
may help | 11 |
study clinical | 11 |
blood volume | 11 |
map kinase | 11 |
musca domestica | 11 |
significantly lower | 11 |
analysis revealed | 11 |
like ace | 11 |
coronavirus pneumonia | 11 |
abdominal attacks | 11 |
mouse models | 11 |
disease states | 11 |
pressure lowering | 11 |
coronavirus receptor | 11 |
internal medicine | 11 |
aldosterone levels | 11 |
factor xia | 11 |
angiotensin iii | 11 |
vitro studies | 11 |
ace activities | 11 |
even though | 11 |
international license | 11 |
significant reduction | 11 |
human coronaviruses | 11 |
inhibition may | 11 |
cerebrospinal fluid | 11 |
expression profiling | 11 |
patients undergoing | 11 |
antihypertensive effects | 11 |
enzyme homologue | 11 |
muscle contraction | 11 |
cardiac hypertrophy | 10 |
two forms | 10 |
protein levels | 10 |
mrna levels | 10 |
severe coronavirus | 10 |
increases ace | 10 |
also shown | 10 |
inhibitory effects | 10 |
therapeutic targets | 10 |
binding motif | 10 |
perfusion pressure | 10 |
regression analysis | 10 |
receptor type | 10 |
novel therapeutic | 10 |
negative feedback | 10 |
conformational change | 10 |
ace shedding | 10 |
large number | 10 |
therapeutic potential | 10 |
circumflex artery | 10 |
null mice | 10 |
ace genes | 10 |
small molecule | 10 |
lower risk | 10 |
fatal outcomes | 10 |
severe heart | 10 |
virus disease | 10 |
receptor antagonism | 10 |
patients suffering | 10 |
higher prevalence | 10 |
increased susceptibility | 10 |
experimental studies | 10 |
nadph oxidase | 10 |
mild disease | 10 |
reduced risk | 10 |
hemodynamic effects | 10 |
arb use | 10 |
per month | 10 |
essential role | 10 |
alzheimer disease | 10 |
treated patients | 10 |
signal peptide | 10 |
modify ace | 10 |
structural studies | 10 |
kinin inactivation | 10 |
wide variety | 10 |
imr cells | 10 |
influenza viruses | 10 |
outcomes among | 10 |
raas inhibition | 10 |
chloride ions | 10 |
inhibitor concentrate | 10 |
significant role | 10 |
hae center | 10 |
somatic angiotensin | 10 |
informed consent | 10 |
arbs may | 10 |
ras dysregulation | 10 |
angiotensin peptide | 10 |
recent years | 10 |
previously reported | 10 |
renal ang | 10 |
renal proximal | 10 |
iconverting enzyme | 10 |
rat ace | 10 |
different mechanisms | 10 |
myocardial contractility | 10 |
induced contraction | 10 |
acei arb | 10 |
contact activation | 10 |
significant effect | 10 |
pulmonary edema | 10 |
zika virus | 10 |
abdominal attack | 10 |
binding interface | 10 |
hormone replacement | 10 |
wall thickness | 10 |
increasing amounts | 10 |
organ failure | 10 |
chinese center | 10 |
cellular entry | 10 |
without affecting | 10 |
general practitioners | 10 |
injury induced | 10 |
class i | 10 |
viral proteins | 10 |
xii activation | 10 |
adult patients | 10 |
case reports | 10 |
negative regulator | 10 |
peptide substrates | 10 |
extracellular matrix | 10 |
ras activity | 10 |
dependent manner | 10 |
failure patients | 10 |
inpatient use | 10 |
vascular endothelium | 10 |
acei arbs | 10 |
treatment options | 10 |
hypertension treatment | 10 |
kininase ii | 10 |
ii stimulates | 10 |
experimental models | 10 |
dry cough | 10 |
mucociliary clearance | 10 |
molecular docking | 10 |
peptide metabolism | 10 |
recent report | 10 |
structural basis | 10 |
ischemic heart | 10 |
based drug | 10 |
airway epithelial | 10 |
lung cancer | 10 |
disease progression | 10 |
like protease | 10 |
vasoactive peptide | 10 |
viral clearance | 10 |
may present | 10 |
aminocaproic acid | 10 |
neprilysin inhibition | 10 |
antihypertensive medications | 9 |
messenger rna | 9 |
arb therapy | 9 |
intestinal wall | 9 |
generating ang | 9 |
coupled receptors | 9 |
clinical benefit | 9 |
cytokine release | 9 |
cardiac arrest | 9 |
ventricular outflow | 9 |
hae attack | 9 |
cell rna | 9 |
black african | 9 |
study conducted | 9 |
innate immunity | 9 |
case report | 9 |
human brain | 9 |
pivotal role | 9 |
drug treatment | 9 |
room temperature | 9 |
much less | 9 |
smoking status | 9 |
addresses concerns | 9 |
kidney diseases | 9 |
terminal dipeptide | 9 |
physiological relevance | 9 |
inhibitors may | 9 |
hospital admission | 9 |
older age | 9 |
reflex tachycardia | 9 |
ace orthologous | 9 |
enzyme responsible | 9 |
type natriuretic | 9 |
ace might | 9 |
alphitobius diaperinus | 9 |
hageman factor | 9 |
family members | 9 |
logistic regression | 9 |
coronary syndrome | 9 |
fold increased | 9 |
pulmonary diseases | 9 |
ii degradation | 9 |
tissue levels | 9 |
also increased | 9 |
least one | 9 |
pig ileum | 9 |
severe lung | 9 |
lockdown policy | 9 |
intravascular coagulation | 9 |
statement addresses | 9 |
wall tension | 9 |
ras imbalance | 9 |
soluble form | 9 |
vivo studies | 9 |
inflammatory mediators | 9 |
left atrium | 9 |
therapeutic approaches | 9 |
fold increase | 9 |
inflammatory markers | 9 |
social distancing | 9 |
postmenopausal women | 9 |
ace ratio | 9 |
ulcerative colitis | 9 |
critical care | 9 |
clinical benefits | 9 |
emerging data | 9 |
lethal covid | 9 |
line therapy | 9 |
performed using | 9 |
per day | 9 |
brain barrier | 9 |
ace insertion | 9 |
lesser mealworm | 9 |
myocardial oxygen | 9 |
tissue sites | 9 |
disseminated intravascular | 9 |
using raas | 9 |
hyperoxic gas | 9 |
serum angiotensin | 9 |
cell growth | 9 |
class iii | 9 |
virus safety | 9 |
pressure reduction | 9 |
increased amounts | 9 |
effective treatment | 9 |
patients showed | 9 |
gene encoding | 9 |
broad spectrum | 9 |
commonly used | 9 |
chronic hepatitis | 9 |
fetal lung | 9 |
express ace | 9 |
peripheral vasodilation | 9 |
angiotensinogen mrna | 9 |
different organs | 9 |
phase depolarization | 9 |
tissue ang | 9 |
catalytic properties | 9 |
blocking drugs | 9 |
york city | 9 |
total deaths | 9 |
generate ang | 9 |
therapeutic effects | 9 |
pneumonia outbreak | 9 |
mg dl | 9 |
circulating levels | 9 |
mice angiotensin | 9 |
endothelial nitric | 9 |
ace structure | 9 |
lupus erythematosus | 9 |
chronic ace | 9 |
statistical significance | 9 |
described previously | 9 |
high concentrations | 9 |
rat kidney | 9 |
arterial pressure | 9 |
structural requirements | 9 |
ace converts | 9 |
low molecular | 9 |
cells angiotensin | 9 |
median age | 9 |
substrate binding | 9 |
pressure control | 9 |
high affinity | 9 |
viral spike | 9 |
total rna | 9 |
therapeutic benefits | 9 |
ng ml | 9 |
glomus cells | 9 |
disease angiotensin | 9 |
ventricular systolic | 9 |
catalytic zinc | 9 |
recombinant soluble | 9 |
dependent inherited | 9 |
vascular inflammation | 9 |
possible mechanisms | 9 |
ace homolog | 9 |
natural products | 9 |
negative charge | 9 |
aha statement | 9 |
dd genotype | 9 |
infected pneumonia | 9 |
human recombinant | 9 |
domain ace | 9 |
proinflammatory cytokines | 9 |
safety profile | 9 |
serum concentrations | 9 |
human tace | 9 |
tissue damage | 9 |
human tissues | 9 |
correlated inversely | 9 |
camostat mesylate | 9 |
gene family | 9 |
critical residues | 9 |
available data | 9 |
reliance level | 9 |
two classes | 9 |
pulmonary arterial | 9 |
elevated levels | 9 |
pilot study | 9 |
highly selective | 9 |
included studies | 9 |
ras blockade | 9 |
high prevalence | 9 |
receptor signaling | 9 |
immunodeficiency virus | 9 |
factors may | 9 |
ang peptides | 9 |
direct renin | 9 |
receptor angiotensin | 9 |
ace polymorphisms | 9 |
high molecular | 8 |
sodium retention | 8 |
study showed | 8 |
performance liquid | 8 |
immune function | 8 |
like symptoms | 8 |
mass spectrometry | 8 |
venous thromboembolism | 8 |
viral particles | 8 |
may potentiate | 8 |
different cell | 8 |
nep expression | 8 |
novel homologue | 8 |
ace enzyme | 8 |
protein coupled | 8 |
ras may | 8 |
circulating angiotensin | 8 |
cell lines | 8 |
stem cell | 8 |
troponin levels | 8 |
potentiating peptide | 8 |
fatty acids | 8 |
peptidyl dipeptidase | 8 |
first case | 8 |
nod mice | 8 |
beneficial effect | 8 |
action potentials | 8 |
normal cardiac | 8 |
antifibrotic effects | 8 |
common side | 8 |
bradykinin receptors | 8 |
without ligand | 8 |
cohort studies | 8 |
gene insertion | 8 |
patients presenting | 8 |
hypertension angiotensin | 8 |
factor viii | 8 |
high dose | 8 |
study population | 8 |
diabetic rats | 8 |
activity may | 8 |
small airway | 8 |
kidney function | 8 |
amyloid beta | 8 |
drugs used | 8 |
water retention | 8 |
releasing hormone | 8 |
two subdomains | 8 |
angiotensin generation | 8 |
proteolytic cleavage | 8 |
lung inflammation | 8 |
sars patients | 8 |
adrenergic receptors | 8 |
cardiovascular function | 8 |
transmembrane serine | 8 |
oxygen consumption | 8 |
severe illness | 8 |
human studies | 8 |
melanogaster ace | 8 |
systemic vascular | 8 |
day follow | 8 |
synergistic effect | 8 |
either ace | 8 |
expression may | 8 |
pulmonary ras | 8 |
germinal ace | 8 |
white group | 8 |
glucose uptake | 8 |
standard care | 8 |
muscle cell | 8 |
many years | 8 |
reactive protein | 8 |
target protease | 8 |
outbreak associated | 8 |
symptomatic heart | 8 |
experimental evidence | 8 |
domain inhibitors | 8 |
two distinct | 8 |
functional characterization | 8 |
raas inhibitors | 8 |
cell signaling | 8 |
tissue factor | 8 |
inflammatory reactions | 8 |
mesangial cells | 8 |
hospitalized covid | 8 |
peptide hormones | 8 |
lymphocyte ratio | 8 |
enzymatically active | 8 |
proteolytic activity | 8 |
hubei province | 8 |
receptors may | 8 |
avian influenza | 8 |
hypoxic pulmonary | 8 |
human immunodeficiency | 8 |
regulated aminopeptidase | 8 |
like enzymes | 8 |
subgroup analysis | 8 |
blocker therapy | 8 |
arbs therapy | 8 |
currently available | 8 |
low dose | 8 |
recorded diagnosis | 8 |
relatively low | 8 |
crystal structures | 8 |
class ii | 8 |
drug therapy | 8 |
better understanding | 8 |
supplementary material | 8 |
whether ace | 8 |
cigarette smoking | 8 |
systemic lupus | 8 |
bk receptor | 8 |
alveolar cells | 8 |
angioedema patients | 8 |
mg kg | 8 |
higher incidence | 8 |
normoxic gas | 8 |
cell cultures | 8 |
septic shock | 8 |
inflammatory responses | 8 |
potentiating compounds | 8 |
current smoking | 8 |
cardiac remodeling | 8 |
evidence suggests | 8 |
myocardial fibrosis | 8 |
lowering blood | 8 |
transmembrane protease | 8 |
less frequently | 8 |
esc council | 8 |
collagen deposition | 8 |
findings suggest | 8 |
bound ace | 8 |
adverse effect | 8 |
national health | 8 |
decreased ang | 8 |
glycemic control | 8 |
renal artery | 8 |
increased vascular | 8 |
left atrial | 8 |
first time | 8 |
lung diseases | 8 |
inflammatory conditions | 8 |
gp recorded | 8 |
homologue ace | 8 |
descending artery | 8 |
angiotensinaldosterone system | 8 |
drug discovery | 8 |
arterial stiffness | 8 |
cardiac fibroblasts | 8 |
regulatory peptides | 8 |
ace paralogous | 8 |
ii metabolism | 8 |
gene duplication | 8 |
human monoclonal | 8 |
signalling pathways | 8 |
mice overexpressing | 8 |
years ago | 8 |
indel polymorphism | 8 |
infected cells | 8 |
future research | 8 |
therapeutic strategy | 8 |
deficiency workshop | 8 |
family medicine | 8 |
intermediate host | 8 |
human angiotensinconverting | 8 |
ras blockers | 8 |
neurological manifestations | 8 |
small study | 8 |
drug development | 8 |
md simulations | 8 |
kallikrein inhibitor | 8 |
inhibit ace | 8 |
collagen synthesis | 8 |
perfused rat | 8 |
terminal active | 8 |
studied tissues | 8 |
docking studies | 8 |
blood meal | 8 |
survival benefit | 8 |
cardiovascular implications | 8 |
germ cells | 8 |
free peritoneal | 8 |
extracellular domain | 8 |
inhibitory peptides | 8 |
studies suggest | 8 |
heterogeneous nuclear | 8 |
serum ace | 8 |
lung epithelial | 8 |
quantitative mrna | 8 |
complement components | 8 |
transmembrane protein | 8 |
dual therapy | 8 |
mortality benefit | 8 |
cell line | 8 |
coronary perfusion | 8 |
adrenal cortex | 8 |
plasma bradykinin | 8 |
enzyme ii | 8 |
critical role | 8 |
ang peptide | 8 |
pressor response | 8 |
alternative splicing | 8 |
mast cell | 8 |
probable bat | 8 |
therapeutic strategies | 8 |
peritoneal fluid | 8 |
enzyme inhibitory | 8 |
body weight | 7 |
function angiotensin | 7 |
norepinephrine release | 7 |
higher ace | 7 |
ras pathway | 7 |
inhibitors reduce | 7 |
two main | 7 |
positive results | 7 |
observed differences | 7 |
nuclear proteins | 7 |
classical axis | 7 |
may influence | 7 |
potentiating action | 7 |
available evidence | 7 |
transcription factor | 7 |
mediates regulated | 7 |
measured using | 7 |
soluble human | 7 |
furin cleavage | 7 |
tace structure | 7 |
biological functions | 7 |
calcium channels | 7 |
receptor agonists | 7 |
preoperative prophylaxis | 7 |
new insights | 7 |
arb treatment | 7 |
increase blood | 7 |
ii induces | 7 |
liver injury | 7 |
prophylactic treatment | 7 |
life cycle | 7 |
cardiovascular complications | 7 |
knockout sperm | 7 |
pulmonary embolism | 7 |
fulminant myocarditis | 7 |
em structure | 7 |
sinus node | 7 |
ece homolog | 7 |
increasing evidence | 7 |
duplication event | 7 |
effective refractory | 7 |
effects associated | 7 |
may exacerbate | 7 |
cov spike | 7 |
phosphinic peptide | 7 |
renal outcomes | 7 |
single gene | 7 |
also demonstrated | 7 |
ace enzymes | 7 |
frontal cortex | 7 |
papillary muscle | 7 |
renal cortex | 7 |
cardiac failure | 7 |
single amino | 7 |
survival study | 7 |
cardiac tissue | 7 |
fluorogenic peptide | 7 |
inhibitors versus | 7 |
inflammatory cells | 7 |
increase ace | 7 |
endocardial cushion | 7 |
last decade | 7 |
differential regulation | 7 |
mutant protein | 7 |
angiotensin iconverting | 7 |
much higher | 7 |
vascular injury | 7 |
positive reference | 7 |
precursor protein | 7 |
may decrease | 7 |
associated angioedema | 7 |
although ace | 7 |
biological effects | 7 |
mortality associated | 7 |
potential influence | 7 |
female mice | 7 |
dextran sulfate | 7 |
group receiving | 7 |
side chains | 7 |
important lessons | 7 |
amyloid angiopathy | 7 |
competitive inhibitors | 7 |
molecular mass | 7 |
blood group | 7 |
commons attribution | 7 |
ace acts | 7 |
significant decrease | 7 |
failing human | 7 |
placebo group | 7 |
activity assay | 7 |
clinical relevance | 7 |
weight gain | 7 |
cov replication | 7 |
papillary muscles | 7 |
carbon atoms | 7 |
potentiating activity | 7 |
skeletal muscle | 7 |
endothelial growth | 7 |
vascular beds | 7 |
early phase | 7 |
systolic blood | 7 |
fold higher | 7 |
cardiac myocytes | 7 |
million people | 7 |
gastric cancer | 7 |
masr axis | 7 |
well established | 7 |
respiratory system | 7 |
clinical management | 7 |
increased incidence | 7 |
also associated | 7 |
sample size | 7 |
ventricular mass | 7 |
danazol therapy | 7 |
spinal cord | 7 |
angioedema attack | 7 |
cardiovascular comorbidities | 7 |
lamina propria | 7 |
factor xi | 7 |
differential expression | 7 |
anopheles gambiae | 7 |
lockdown measures | 7 |
sex differences | 7 |
vaccine arrival | 7 |
per million | 7 |
brain angiotensin | 7 |
arb drugs | 7 |
inositol phosphates | 7 |
ii accumulation | 7 |
cardiac action | 7 |
untreated patients | 7 |
ace gpiase | 7 |
difficulty breathing | 7 |
medical research | 7 |
coronavirus entry | 7 |
independent predictors | 7 |
expressing cells | 7 |
metabolic syndrome | 7 |
pressure homeostasis | 7 |
additional file | 7 |
renal tubules | 7 |
induced diabetic | 7 |
tricuspid valve | 7 |
inhibitor captopril | 7 |
total number | 7 |
direct evidence | 7 |
commercially available | 7 |
virtual screening | 7 |
genome sequence | 7 |
rat liver | 7 |
lesser extent | 7 |
new target | 7 |
vasopeptidase inhibitor | 7 |
evidence supporting | 7 |
ventricular remodeling | 7 |
interim guidance | 7 |
coronavirus associated | 7 |
calcium levels | 7 |
blind placebo | 7 |
drug administration | 7 |
main protease | 7 |
human transmission | 7 |
sore throat | 7 |
ace null | 7 |
cells via | 7 |
like peptide | 7 |
associated coronavirus | 7 |
molecular level | 7 |
carbohydrate groups | 7 |
bar chart | 7 |
biochemical indexes | 7 |
total protein | 7 |
treatment may | 7 |
worse outcomes | 7 |
levels may | 7 |
infect humans | 7 |
neprilysin inhibitors | 7 |
ncov infected | 7 |
body mass | 7 |
left circumflex | 7 |
primary outcome | 7 |
pacemaker cells | 7 |
increased angiotensin | 7 |
synthase inhibition | 7 |
mass index | 7 |
terminal part | 7 |
new class | 7 |
chart showing | 7 |
pilot clinical | 7 |
blood supply | 7 |
mouse brain | 7 |
vasoprotective axes | 7 |
current evidence | 7 |
receptor may | 7 |
two enzymes | 7 |
indirect deaths | 7 |
heat shock | 7 |
kinin receptor | 7 |
mm tris | 7 |
peptide ang | 7 |
direct effect | 7 |
upper airway | 7 |
chest pain | 7 |
carboxypeptidase angiotensin | 7 |
therapeutic option | 7 |
lower ace | 7 |
study using | 7 |
studied tissue | 7 |
degrading enzymes | 7 |
active peptides | 7 |
plasma angiotensin | 7 |
direct interaction | 7 |
million cases | 7 |
post hoc | 7 |
proteolytic processing | 7 |
based study | 7 |
acid sequences | 7 |
bk degradation | 7 |
regulated ectodomain | 7 |
low levels | 7 |
increased plasma | 7 |
pathway activation | 7 |
also present | 7 |
domain selectivity | 7 |
bradykinin generation | 7 |
less severe | 7 |
adverse outcomes | 7 |
renal failure | 7 |
hepatic stellate | 7 |
cell receptor | 7 |
icu patients | 7 |
african descent | 7 |
intermediate hosts | 7 |
reproductive system | 7 |
mean age | 7 |
ventricular function | 7 |
heavily glycosylated | 7 |
single domain | 7 |
testing positive | 7 |
circulatory system | 7 |
edema formation | 7 |
lipid raft | 7 |
bk action | 7 |
results showed | 7 |
ii ang | 7 |
domain active | 7 |
membrane bound | 7 |
induced angioedema | 7 |
invertebrate ace | 7 |
cellular receptor | 7 |
antibody responses | 7 |
creatine kinase | 7 |
disease expression | 7 |
carotid body | 7 |
cardiogenic shock | 7 |
cardiac conditions | 7 |
human sace | 7 |
hospitalised patients | 7 |
renal fibrosis | 7 |
laboratory diagnosis | 7 |
human vascular | 7 |
subfornical organ | 7 |
term treatment | 7 |
pichia pastoris | 7 |
renal tubular | 7 |
patients linked | 7 |
protein interaction | 7 |
active metabolite | 7 |
peripheral blood | 7 |
conformational changes | 6 |
human testis | 6 |
growth factors | 6 |
among african | 6 |
inh functional | 6 |
two large | 6 |
plate reader | 6 |
facilitating viral | 6 |
prevents tgf | 6 |
therapeutic options | 6 |
scientific societies | 6 |
significant increases | 6 |
functional conservation | 6 |
coronary heart | 6 |
higher expression | 6 |
human somatic | 6 |
initial conditions | 6 |
key differences | 6 |
ace genotype | 6 |
significant effects | 6 |
carboxyl group | 6 |
ii effects | 6 |
arg bradykinin | 6 |
lipid metabolism | 6 |
intrarenal renin | 6 |
acute phase | 6 |
like peptides | 6 |
ace receptors | 6 |
severe sars | 6 |
reduced left | 6 |
clinical improvement | 6 |
gene deletion | 6 |
first ace | 6 |
severe abdominal | 6 |
cardiology american | 6 |
cardiac events | 6 |
prevent sars | 6 |
human body | 6 |
impulse generation | 6 |
serum levels | 6 |
cell membranes | 6 |
enzymatic degradation | 6 |
highly conserved | 6 |
rheumatoid arthritis | 6 |
signaling pathway | 6 |
human coronary | 6 |
alternate promoters | 6 |
including hypertension | 6 |
negatively charged | 6 |
novel virus | 6 |
lung function | 6 |
autoimmune diseases | 6 |
ligand interactions | 6 |
receptor upregulation | 6 |
two axes | 6 |
follicle wall | 6 |
van der | 6 |
high plasma | 6 |
hypotensive effect | 6 |
serum albumin | 6 |
physiological function | 6 |
prefusion conformation | 6 |
complete protease | 6 |
health records | 6 |
gene transfer | 6 |
receptor knockout | 6 |
local angiotensin | 6 |
low doses | 6 |
prospective cohort | 6 |
systolic dysfunction | 6 |
type diabetic | 6 |
open reading | 6 |
general reliance | 6 |
unless otherwise | 6 |
heme oxygenase | 6 |
domain protein | 6 |
protein structure | 6 |
commons licence | 6 |
intrinsic pathway | 6 |
vascular leakage | 6 |
vital role | 6 |
cardiac injury | 6 |
also expressed | 6 |
epithelial cell | 6 |
endothelin converting | 6 |
motion important | 6 |
vascular events | 6 |
diastolic depolarization | 6 |
kinin formation | 6 |
may serve | 6 |
ace cleaves | 6 |
cell fusion | 6 |
objective function | 6 |
receptor neprilysin | 6 |
angioedema may | 6 |
mouse kidney | 6 |
vascular damage | 6 |
positive patients | 6 |
human health | 6 |
relative risk | 6 |
drug targets | 6 |
mm hg | 6 |
hematopoietic stem | 6 |
molecular dynamics | 6 |
may regulate | 6 |
lcz group | 6 |
chronic diseases | 6 |
primary structure | 6 |
point mutations | 6 |
major cardiovascular | 6 |
small number | 6 |
peptide receptor | 6 |
testicular ace | 6 |
therapeutic agent | 6 |
ff complement | 6 |
treated cells | 6 |
bombyx mori | 6 |
antiviral compounds | 6 |
nuclear ribonucleoprotein | 6 |
relatively small | 6 |
sinoatrial node | 6 |
confounding variables | 6 |
may prevent | 6 |
multiple sclerosis | 6 |
vasopeptidase inhibition | 6 |
porcine coronary | 6 |
human receptor | 6 |
pathogenic coronaviruses | 6 |
released egfp | 6 |
functional ace | 6 |
atrioventricular node | 6 |
dyax corp | 6 |
concomitant use | 6 |
many countries | 6 |
potential risk | 6 |
transmission dynamics | 6 |
blood cells | 6 |
protein releasing | 6 |
deduced amino | 6 |
also plays | 6 |
type plasminogen | 6 |
receptor subtype | 6 |
usually associated | 6 |
shock protein | 6 |
positively charged | 6 |
rabbit lung | 6 |
activity correlated | 6 |
human respiratory | 6 |
peripheral vasodilator | 6 |
systemic blood | 6 |
potentiating nonapeptide | 6 |
high glucose | 6 |
disease patients | 6 |
human tissue | 6 |
raas components | 6 |
million reads | 6 |
biochemical properties | 6 |
inhibitor rxpa | 6 |
ras activation | 6 |
practice guidelines | 6 |
least two | 6 |
study design | 6 |
nh mutations | 6 |
angiotensin production | 6 |
cigarette use | 6 |
cov receptor | 6 |
available online | 6 |
mg day | 6 |
descriptive study | 6 |
systemic inflammatory | 6 |
online version | 6 |
following myocardial | 6 |
global pandemic | 6 |
theromyzon tessulatum | 6 |
intestinal absorption | 6 |
sympathetic activity | 6 |
increased blood | 6 |
cerebral amyloid | 6 |
epidemiological studies | 6 |
reactive center | 6 |
functional roles | 6 |
av node | 6 |
transmembrane potential | 6 |
zinc binding | 6 |
higher affinity | 6 |
ns md | 6 |
nucleic acid | 6 |
often associated | 6 |
hypertensive rat | 6 |
binding channel | 6 |
viral genome | 6 |
unclear whether | 6 |
lv ejection | 6 |
potentiating factors | 6 |
cardiovascular morbidity | 6 |
unpublished data | 6 |
never smokers | 6 |
sudden cardiac | 6 |
guanylate cyclase | 6 |
competitive inhibitor | 6 |
increase susceptibility | 6 |
human beings | 6 |
vasomotor tone | 6 |
hospital setting | 6 |
bradykinin levels | 6 |
viral pneumonia | 6 |
systemic hypertension | 6 |
higher rates | 6 |
male mice | 6 |
reproduction number | 6 |
pressure effects | 6 |
virus transmission | 6 |
international committee | 6 |
average age | 6 |
human angiotensinogen | 6 |
inhibitor omapatrilat | 6 |
reactive site | 6 |
multivariate analysis | 6 |
diabetic animals | 6 |
original sars | 6 |
tau pathology | 6 |
share sequence | 6 |
clinical evidence | 6 |
carboxypeptidase activity | 6 |
soluble fraction | 6 |
tissue samples | 6 |
renal damage | 6 |
cytokine production | 6 |
drugs may | 6 |
disease susceptibility | 6 |
giving rise | 6 |
national institute | 6 |
existing hypertension | 6 |
therapy program | 6 |
scientific evidence | 6 |
since ace | 6 |
among others | 6 |
systemic circulation | 6 |
cystic ovaries | 6 |
dd polymorphism | 6 |
leech theromyzon | 6 |
trend towards | 6 |
regulate ace | 6 |
repurposed drugs | 6 |
analysis showed | 6 |
zinc metallopeptidase | 6 |
severe pneumonia | 6 |
may vary | 6 |
inflammatory drugs | 6 |
serpin function | 6 |
inflammatory pathways | 6 |
deceased patients | 6 |
av nodal | 6 |
septal perforators | 6 |
releasing peptide | 6 |
convert ang | 6 |
wet market | 6 |
consecutive patients | 6 |
respiratory infection | 6 |
within days | 6 |
organ dysfunction | 6 |
two catalytic | 6 |
basal level | 6 |
cardiac ischemia | 6 |
proprotein convertases | 6 |
adenylate cyclase | 6 |
rat models | 6 |
may provoke | 6 |
combination therapy | 6 |
left anterior | 6 |
spectrum antiviral | 6 |
expert group | 6 |
aventis behring | 6 |
degradation products | 6 |
frequently used | 6 |
prion protein | 6 |
binding properties | 6 |
may produce | 6 |
aged years | 6 |
neurogenic hypertension | 6 |
randomised controlled | 6 |
potentiating factor | 6 |
tissue plasminogen | 6 |
spontaneous diastolic | 6 |
asymptomatic individuals | 6 |
kinin peptide | 6 |
cellular protease | 6 |
early studies | 6 |
ii angiotensin | 6 |
great deal | 6 |
anterior descending | 6 |
hypotensive effects | 6 |
vascular bed | 6 |
regulates ace | 6 |
virus validation | 6 |
plasma ang | 6 |
neutrophil elastase | 6 |
apoptotic cells | 6 |
negative inotropy | 6 |
remote work | 6 |
putative receptor | 6 |
hydrophobic interactions | 6 |
hospitalised covid | 6 |
shr kidney | 6 |
reduced mortality | 6 |
genetic analysis | 6 |
ventricular ejection | 6 |
ad compared | 6 |
validation studies | 6 |
docking score | 6 |
become infected | 6 |
metabolic disorders | 6 |
underlying conditions | 6 |
emerging evidence | 6 |
lower blood | 6 |
proxy measure | 6 |
two ace | 6 |
selective ace | 6 |
systematic reviews | 6 |
chronic liver | 6 |
future studies | 6 |
patients developed | 6 |
force field | 6 |
vascular complications | 6 |
common symptoms | 6 |
pulmonic valve | 6 |
cysteine residues | 6 |
serum potassium | 6 |
sympathetic activation | 6 |
septum primum | 6 |
free periods | 6 |
activation via | 6 |
locusta migratoria | 6 |
activity levels | 6 |
alkaline phosphatase | 6 |
human kidney | 6 |
ii via | 6 |
gene knockout | 6 |
renovascular hypertension | 6 |
target proteases | 6 |
inactivation pathways | 6 |
culture medium | 6 |
estrogen replacement | 6 |
severe aortic | 6 |
sequence similarity | 6 |
elevated ace | 6 |
adjusted odds | 6 |
significantly elevated | 6 |
clinical parameters | 6 |
correct diagnosis | 6 |
supporting information | 6 |
tentative sars | 6 |
intracellular signaling | 6 |
beneficial role | 6 |
structures reveal | 6 |
using different | 6 |
radial immunodiffusion | 6 |
high doses | 6 |
women taking | 6 |
melanogaster ance | 6 |
current situation | 6 |
lisinopril complex | 6 |
release syndrome | 6 |
ii hereditary | 6 |
randomized trials | 6 |
type calcium | 6 |
inh mutants | 6 |
previously described | 6 |
vivo models | 6 |
supportive care | 6 |
porphyromonas gingivalis | 6 |
sympathetic tone | 6 |
male gender | 6 |
initial docking | 6 |
anopheles stephensi | 6 |
cell activation | 6 |
randomized control | 6 |
mediated vasodilation | 6 |
biochemical characterization | 6 |
hoc analysis | 6 |
without eliciting | 6 |
patients received | 6 |
inh autoantibodies | 6 |
renal expression | 6 |
adjusted hrs | 6 |
charge distribution | 6 |
emergency department | 6 |
physiological roles | 6 |
anoace homologues | 6 |
specific primers | 6 |
dilated cardiomyopathy | 6 |
many tissues | 6 |
docking pose | 6 |
genetic variants | 6 |
may indicate | 6 |
previously shown | 6 |
dimensional structure | 6 |
linked glycosylation | 6 |
respiratory infections | 6 |
severe attacks | 6 |
class ic | 6 |
platelet activation | 6 |
kell blood | 6 |
secondary prevention | 6 |
first evidence | 6 |
western blot | 6 |
johns hopkins | 6 |
central role | 6 |
lower mortality | 6 |
ace homologs | 6 |
expression within | 6 |
antihypertensive efficacy | 6 |
ras inhibitors | 6 |
inverse relationship | 6 |
studies also | 6 |
may exert | 6 |
peptide formation | 6 |
ii also | 6 |
site residues | 6 |
endothelin system | 6 |
renal tissue | 6 |
pulmonary neuroendocrine | 6 |
artery stenosis | 6 |
angioedema due | 6 |
catalytic efficiency | 6 |
platelet aggregation | 6 |
high incidence | 5 |
respiratory virus | 5 |
pulmonary injury | 5 |
thromboembolic events | 5 |
related disorders | 5 |
aldosterone production | 5 |
decompensated heart | 5 |
tmprss protease | 5 |
note springer | 5 |
patients presented | 5 |
also increase | 5 |
antithrombotic effect | 5 |
increased glomerular | 5 |
kidney failure | 5 |
ace imbalance | 5 |
month intervals | 5 |
major mediator | 5 |
irritans exigua | 5 |
serum ang | 5 |
mortality risk | 5 |
binding energy | 5 |
acid replacements | 5 |
ii clinical | 5 |
therapy may | 5 |
endogenous ligand | 5 |
oral contraceptives | 5 |
studies reported | 5 |
site zinc | 5 |
medical treatment | 5 |
therapeutic interventions | 5 |
circulating renin | 5 |
jurisdictional claims | 5 |
fluorogenic substrate | 5 |
catalytic mechanism | 5 |
channel blocker | 5 |
chinese patients | 5 |
subcutaneous insulin | 5 |
putative ace | 5 |
people infected | 5 |
potassium levels | 5 |
increased myocardial | 5 |
may potentially | 5 |
comorbid conditions | 5 |
inhibitor design | 5 |
nature remains | 5 |
facilitate viral | 5 |
three different | 5 |
ed admission | 5 |
similar results | 5 |
renal impairment | 5 |
foramen ovale | 5 |
risk individuals | 5 |
thromboembolic disease | 5 |
aii levels | 5 |
potential conflict | 5 |
glucose control | 5 |
extensively studied | 5 |
second wave | 5 |
like syndrome | 5 |
rat intestine | 5 |
inhibition improves | 5 |
carboxypeptidase ace | 5 |
single active | 5 |
tumor growth | 5 |
derived peptides | 5 |
still unclear | 5 |
negative inotropic | 5 |
hae caused | 5 |
bundle branch | 5 |
weight heparin | 5 |
china medical | 5 |
transgenic animals | 5 |
santa cruz | 5 |
african american | 5 |
vascular system | 5 |
rmsd values | 5 |
ii level | 5 |
ancestral ace | 5 |
domain structure | 5 |
cirrhotic patients | 5 |
angioedema without | 5 |
will need | 5 |
noncardiac surgery | 5 |
ligand complexes | 5 |
consensus sequence | 5 |
urinary excretion | 5 |
age years | 5 |
volume overload | 5 |
short periods | 5 |
systemic inflammation | 5 |
novel peptide | 5 |
saudi arabia | 5 |
broad substrate | 5 |
prove beneficial | 5 |
treatment group | 5 |
antibody specific | 5 |
oral ace | 5 |
paralogous gene | 5 |
clinically significant | 5 |
eliciting reflex | 5 |
increased frequency | 5 |
prostate cancer | 5 |
less effective | 5 |
intracellular ca | 5 |
media thickness | 5 |
ischaemic stroke | 5 |
estrogen therapy | 5 |
recent reports | 5 |
relatively high | 5 |
care alone | 5 |
agt gene | 5 |
study reported | 5 |
bending motion | 5 |
albumin excretion | 5 |
another report | 5 |
inhibitor use | 5 |
alveolar damage | 5 |
ethnic group | 5 |
also suggest | 5 |
inhibitor angiotensin | 5 |
airway obstruction | 5 |
mechanical trauma | 5 |
extracellular signal | 5 |
analysis based | 5 |
specific expression | 5 |
regulated membrane | 5 |
i receptor | 5 |
hyperoxic lung | 5 |
positive disease | 5 |
entry receptor | 5 |
ventricular fibrillation | 5 |
immunity threshold | 5 |
serial interval | 5 |
nep inhibitors | 5 |
interatrial septum | 5 |
ace inhibitory | 5 |
neutrophil infiltration | 5 |
also revealed | 5 |
deficiency angioedema | 5 |
respiratory symptoms | 5 |
inflammatory lung | 5 |
springer nature | 5 |
pressure response | 5 |
denotes covid | 5 |
lockdown levels | 5 |
cdna encoding | 5 |
cord blood | 5 |
plant food | 5 |
novel activity | 5 |
stimulated gene | 5 |
cho cells | 5 |
drug repurposing | 5 |
without ace | 5 |
primary endpoint | 5 |
slightly higher | 5 |
confidence intervals | 5 |
published maps | 5 |
membrane anchor | 5 |
heart rhythm | 5 |
coronary revascularization | 5 |
block sars | 5 |
viral invasion | 5 |
structural features | 5 |
ii trial | 5 |
severe respiratory | 5 |
juxtaglomerular apparatus | 5 |
effective therapeutic | 5 |
pcr positive | 5 |
nonpeptide agonist | 5 |
acute kidney | 5 |
care workers | 5 |
different clinical | 5 |
willebrand factor | 5 |
may worsen | 5 |
mcg kg | 5 |
cl protease | 5 |
selective inhibition | 5 |
new angiotensin | 5 |
vivo substrates | 5 |
reduce mortality | 5 |
wing discs | 5 |
stranded rna | 5 |
also acts | 5 |
study investigators | 5 |
antiviral response | 5 |
kidney angiotensin | 5 |
allele frequency | 5 |
drugs targeting | 5 |
multicenter study | 5 |
neurodegenerative diseases | 5 |
alternative pathways | 5 |
kidney damage | 5 |
angiotensin blockade | 5 |
reverse transcriptase | 5 |
care units | 5 |
ethics committee | 5 |
diagnostic tool | 5 |
population reaches | 5 |
reperfusion injury | 5 |
chloride dependence | 5 |
may induce | 5 |
current study | 5 |
severe exacerbation | 5 |
effects via | 5 |
ace pathways | 5 |
hepatic metabolism | 5 |
symptom onset | 5 |
put forward | 5 |
hypertensive drugs | 5 |
inflammatory properties | 5 |
might provide | 5 |
system also | 5 |
portal hypertensive | 5 |
small intestinal | 5 |
even higher | 5 |
physiological conditions | 5 |
higher susceptibility | 5 |
heparin octasaccharide | 5 |
worse prognosis | 5 |
key modulator | 5 |
liver function | 5 |
therapeutic agents | 5 |
ace differentially | 5 |
viral testing | 5 |
neurotransmitter release | 5 |
experimental lung | 5 |
sars epidemic | 5 |
clinical effect | 5 |
heart attack | 5 |
significant change | 5 |
aldosterone antagonists | 5 |
closely resembles | 5 |
left coronary | 5 |
mutation database | 5 |
cytokine storms | 5 |
ance expression | 5 |
angioedema hereditary | 5 |
electronic health | 5 |
table vi | 5 |
cardiac pacemaker | 5 |
ambulatory blood | 5 |
mononuclear cells | 5 |
congestive cardiac | 5 |
edged sword | 5 |
components required | 5 |
dependent pathway | 5 |
coronavirus diseases | 5 |
best binding | 5 |
closely related | 5 |
domain selective | 5 |
two years | 5 |
new type | 5 |
recent advances | 5 |
heart block | 5 |
developing angioedema | 5 |
limited information | 5 |
clinical significance | 5 |
coronavirus replication | 5 |
recombinant xcace | 5 |
angiotensin aldosterone | 5 |
apical surface | 5 |
effective dose | 5 |
amersham bioscience | 5 |
heart angiotensin | 5 |
soluble angiotensin | 5 |
domain angiotensin | 5 |
kinin receptors | 5 |
pneumonia associated | 5 |
fetal human | 5 |
black bars | 5 |
mesenchymal cells | 5 |
rat rptcs | 5 |
several reports | 5 |
including ace | 5 |
higher plasma | 5 |
data indicate | 5 |
induced oxidative | 5 |
tissue renin | 5 |
male reproductive | 5 |
vasodilatory effect | 5 |
term therapy | 5 |
healthy subjects | 5 |
future treatment | 5 |
diffuse alveolar | 5 |
active angiotensin | 5 |
angioedema symptoms | 5 |
may therefore | 5 |
interquartile range | 5 |
increased covid | 5 |
chronic renal | 5 |
also include | 5 |
positive correlation | 5 |
different types | 5 |
rna virus | 5 |
ace variants | 5 |
oral administration | 5 |
peptide ac | 5 |
containing mm | 5 |
bile duct | 5 |
direct myocardial | 5 |
viral protein | 5 |
entry replication | 5 |
myocardial dysfunction | 5 |
target organ | 5 |
one may | 5 |
multiple biological | 5 |
two alternate | 5 |
elevated ang | 5 |
pattern recognition | 5 |
cell damage | 5 |
may act | 5 |
type iv | 5 |
ras plays | 5 |
fluid homeostasis | 5 |
egg binding | 5 |
likely results | 5 |
receptors mediate | 5 |
studies reporting | 5 |
human small | 5 |
age groups | 5 |
lower airways | 5 |
kininase i | 5 |
tested positive | 5 |
acid glycosides | 5 |
healthcare workers | 5 |
experimental study | 5 |
like immunoreactivity | 5 |
axis may | 5 |
patients whose | 5 |
polymorphism may | 5 |
severely ill | 5 |
main effector | 5 |
improve outcomes | 5 |
genetic polymorphism | 5 |
reflex sympathetic | 5 |
increased renal | 5 |
molecule inhibitors | 5 |
extracellular space | 5 |
length human | 5 |
der waals | 5 |
human serum | 5 |
activity assays | 5 |
expression via | 5 |
antihypertensive treatment | 5 |
cleaves gpi | 5 |
domain form | 5 |
authors report | 5 |
stable angina | 5 |
med doi | 5 |
two different | 5 |
encoding ace | 5 |
markedly increased | 5 |
stellate cells | 5 |
segment elevation | 5 |
protein may | 5 |
small interfering | 5 |
activated factor | 5 |
therapeutic efficacy | 5 |
zona pellucida | 5 |
genomic characterisation | 5 |
escherichia coli | 5 |
also reported | 5 |
patients reported | 5 |
pulmonary damage | 5 |
treatment protocols | 5 |
multiple studies | 5 |
active form | 5 |
serum complement | 5 |
intrinsic rate | 5 |
idiopathic pulmonary | 5 |
raas blockers | 5 |
acidic ph | 5 |
induced endothelial | 5 |
high viral | 5 |
human cell | 5 |
key components | 5 |
water absorption | 5 |
cardiac vein | 5 |
literature review | 5 |
competing interests | 5 |
like gene | 5 |
may reduce | 5 |
body fluids | 5 |
peptide angiotensin | 5 |
significantly different | 5 |
treat hypertension | 5 |
cultured human | 5 |
twice daily | 5 |
prorenin levels | 5 |
rat effect | 5 |
virus infections | 5 |
thrombotic complications | 5 |
association task | 5 |
terminal sequence | 5 |
case rep | 5 |
quinovic acid | 5 |
pathways involving | 5 |
multiple organ | 5 |
institutional affiliations | 5 |
global health | 5 |
circulating coronaviruses | 5 |
receptor mediates | 5 |
controlled randomized | 5 |
cov virus | 5 |
severe complications | 5 |
matrix proteins | 5 |
regulatory role | 5 |
ovarian follicular | 5 |
experimental diabetes | 5 |
human disease | 5 |
zinc metalloproteinase | 5 |
airway disease | 5 |
erythema marginatum | 5 |
critical aminoacids | 5 |
braak tangle | 5 |
ece activity | 5 |
kidney proximal | 5 |
i statistics | 5 |
gene coding | 5 |
change ace | 5 |
test results | 5 |
bradykinin peptides | 5 |
potential benefit | 5 |
oxide production | 5 |
oral submucous | 5 |
blood coagulation | 5 |
ii may | 5 |
will also | 5 |
neuroendocrine cells | 5 |
homologue ance | 5 |
myocardial infarct | 5 |
detrimental effects | 5 |
clinical signs | 5 |
kinetic studies | 5 |
bronchial epithelial | 5 |
may provide | 5 |
infarct size | 5 |
global threat | 5 |
amyloid peptide | 5 |
zinc dependent | 5 |
highly similar | 5 |
great interest | 5 |
clinical condition | 5 |
highly specific | 5 |
study provided | 5 |
forming enzymes | 5 |
counts per | 5 |
glass opacities | 5 |
short duration | 5 |
viral respiratory | 5 |
virus origins | 5 |
lacking angiotensin | 5 |
edematous swelling | 5 |
submucous fibrosis | 5 |
obese diabetic | 5 |
cellular responses | 5 |
lactate dehydrogenase | 5 |
regulate blood | 5 |
via angiotensin | 5 |
extracellular fluid | 5 |
mediated reduction | 5 |
control animals | 5 |
recent findings | 5 |